Ipix perked up again this year because of Covid
Covid plays are still hot... just like EV and Bitcoin
The Covid data so far seems good for IPIX, but it's preclinical. Right now we are the turning point of getting into human trials. It's a risk/reward play. Will our lead Covid drug candidate do well in human trials? That's a gamble you have to make
Other reasons why the stock is not yet in rally mode. The company PRs are not very direct, but give more or less a general idea. Many times investors are left with more questions then answers. The time frames given in company PRs are not to be relied upon. The company disappears when bad news arises. Toxic financing has hurt the share price without concrete news to back it up.
Positives include our now active IND, a pre-print out of George Mason Univ and Rutgers covering our lead Covid drug (however not peer reviewed yet), cash in the bank, Covid drug has already been manufactured, several CROs in place (domestic and overseas) to start trials
Speculation include grant money, new partner/collaborator, update on other indications, good P2 results, new arms included in clinical studies for pan-coronavirus, new pre-prints coming out on lead Covid candidate
Happy New Year